胃幽门螺杆菌感染与口臭的相关性研究

目的:探讨胃幽门螺杆菌感染与口臭发生的相关性。方法:选取48例口臭患者为研究对象,另选取96例无口臭的健康志愿者为无口臭组,通过13C呼气试验检测所有研究对象幽门螺杆菌的感染情况,比较两组幽门螺杆菌的感染率。根据是否感染幽门螺杆菌分为感染组和无感染组,比较两组口臭的发生率,分析幽门螺杆菌感染与口臭发生的相关性。结果:口臭组和非口臭组患者幽门螺杆菌的感染率分别为79.17%,27.08%,口臭组显著高于无口臭组,差异有统计学意义(x2=35.16,P0.05)。口臭与幽门螺杆菌的感染显著相关(r=0.4)。幽门螺杆菌感染组患者和未感染组口臭的发生率分别为70.31%和3.75%,感染组显著高于未感染组,差异有统计学意义(x2=70.89,P0.05)。幽门螺杆菌的感染与口臭的发生率显著相关(r=0.69)。结论:幽门螺杆菌感染与口臭的发生有密切的相关性,是引起口臭的一个重要因素。     

胃息肉与幽门螺杆菌感染关系研究

目的探讨胃息肉与幽门螺杆菌（Helicobacter pylori,H.pylori）感染关系。方法对1218例胃息肉同时进行H．pylori检查患者进行回顾性分析,分析胃息肉患者H.pylori感染率、胃息肉部位与H.pylori感染关系、胃息肉病理类型与H.pylori感染关系。结果发现胃息肉Hpylori感染患者532例,Hpylori感染率为43．7％。男性胃息肉患者H.pylori感染率为47．5％（216／455）,女性Hpriori感染率感染率为41．4％（316／763）（P〉0．05）,年龄〈20岁、20～39岁、40—59岁和≥60岁胃息肉H.priori感染率分别为41．7％、44．7％、41．6％和47．2％（P〉0．05）;胃窦胃角息肉H.pylori感染率高于其他部位（胃体、胃底和贲门）（P〈0．05）;炎性和增生性胃息肉H.priori感染率高于胃底腺和腺瘤性息肉（P〈0．05）。结论H.pylori感染可能与部分胃息肉发生有一定关系,需要进一步深入研究胃息肉的发生机制。     

幽门螺杆菌感染与冠心病

幽门螺杆菌感染与慢性胃炎、消化性溃疡的发病密切相关。近年来的研究还发现,幽门螺杆菌感染可能与冠心病发病也有关系,但其机制仍不清楚,可能与炎症免疫反应、高半胱氨酸血症、脂质代谢紊乱、促凝物质增加等因素有关。进一步探讨其作用机制将为冠心病的防治提供一条新的途径。     

幽门螺杆菌感染免疫逃逸机制的研究

研制有效的幽门螺杆菌疫苗,是防治该菌感染的有效途径。本文综述幽门螺杆菌感染的免疫逃逸机制的研究进展,以便深入了解幽门螺杆菌慢性感染的机制,为研制疫苗提供新的思路。     

幽门螺杆菌感染与血浆obestatin水平的关系研究

目的：obestatin是新发现的与肥胖相关的多肽,本研究探讨幽门螺杆菌（H．pylori）对体重指数（BMI）~LM浆obestatin水平的影响。方法：于我院体检中心入选健康体检者205例,所有入选者无明确的胃肠疾病史,无心脏、肾脏、肝脏、甲状腺等疾病病史,无急性感染等其他可能影响激素水平的因素。幽门螺杆菌的感染依据l3C呼气实验及血清学指标联合判定。应用放射免疫分析法测定血浆obestatin及血清胰岛素水平。血清血脂水平采用自动生化分析仪进行酶法测定。胰岛素抵抗采用胰岛素抵抗指数（HOMA-IR）评定,HOMA—IR=空腹胰岛素（p~IU／ml）x空腹血糖（mmol／L）／22．5。结果：在我们的75例研究对象中H．pylori阳性的检出率为39％,幽门螺杆菌感染阳性者与阴性者相比,体重指数（BMI）差异并无统计学意义,血浆obestafin水平无显著性的差异。按体重指数进行分组,BMI〉24kg／m2组与BMI〈24kg／m2相比血浆obestatin水平明显下降。结论：H．pylori的感染状态并没有显著影响个体的循环obestatin水平。BMI对血浆obestatin水平有影响。     

肝硬化患者幽门螺杆菌感染与血氨的关系

目的 :探讨幽门螺杆菌 (Hp)感染对肝硬化患者血氨浓度的影响。 方法 :35例肝硬化患者及 2 5例消化性溃疡患者分别测定Hp感染情况及空腹血氨浓度 ,对于Hp阳性病人口服质子泵抑制剂三联方案1周后测定空腹血氨。结果 :Hp阳性的肝硬化患者空腹血氨较Hp阴性的肝硬化患者空腹血氨显著升高(P <0 0 1)。根除Hp后 ,肝硬化患者空腹血氨浓度显著下降 (P <0 0 5 )。 结论 :Hp感染可引起肝硬化患者血氨浓度升高 ,对此类患者采用Hp根除治疗 ,可显著降低血氨浓度。抗Hp治疗可能有助于预防及治疗肝硬化患者的高氨血症及由此诱发的肝性脑病及亚临床肝性脑病。     

儿童慢性牙周炎与口腔幽门螺杆菌感染的相关性

目的 探讨慢性牙周炎患儿与其口腔中幽门螺杆菌(Helicobacter pylori, H. pylori)的相关性,为儿童慢性牙周炎的临床治疗提供指导。 方法 分别随机选取2017年5月-2019年5月来我院口腔科就诊的慢性牙周炎患儿和牙周健康的儿童作为观察组(92例)和对照组(92例)。应用PCR技术检测采集的牙菌斑和含漱液样品中的H. pylori,并比较两组儿童口腔H. pylori检出率的差异及龈上、龈下菌斑中的分布情况以及不同程度牙周炎患儿检出率的差异。 结果 观察组患儿口腔中H. pylori的检出率明显高于对照组,两组之间差异有统计学意义(χ2=9.588 1,P2= 58.119 9,P2=19.783 1,P结论 口腔中H. pylori可能在儿童慢性牙周炎致病过程具有一定的促进作用,二者具有相关性。     

儿童幽门螺杆菌感染

幽门螺杆菌感染不仅能引起胃炎、消化性溃疡,诱发胃癌等胃肠道的病变,还与许多胃肠外疾病密切相关,如果不经过特殊治疗将终生带菌,严重的影响小儿的生长发育和身心健康。这些问题引起了儿科医生和儿童保健医生的共同关注。儿童期既是幽门螺杆菌感染的特殊时期,也是控制感染的关键时期。本文将从小儿幽门螺杆菌国内外的感染状况、相关疾病、诊断方法、治疗及预防等几个方面综述如下。     

幽门螺杆菌疫苗的研究现状

幽门螺杆菌（ＨＨ）是慢性胃炎和消化性溃疡的主要病因,并与胃癌的发生密切相关,其相关致病因子主要包括尿素酶、细胞粘附素、过氧化氢酶、脂酶、蛋白酶、细菌毒素和能导致炎症反应的物质。ＨＰ的致病机理与ＨＰ的致病性和宿主免疫应答有关,尤以细菌的毒性占主导地位。近年来国内外均关注ＨＰ的免疫预防和治疗。由于ＨＰ减毒活疫苗的研究条件尚不成熟,目前正重点进行全菌体死疫苗、组分疫苗及基因工程疫苗的研究,ＨＰ动物模型、疫苗的免疫途径、免疫佐剂的研究已取得了令人满意的进展,ＨＰ疫苗的治疗作用更引起了人们的关注。本文对ＨＰ的致病机理、疫苗的研究进展等做一综述。     

幽门螺杆菌与胃癌关系的研究进展

幽门螺杆菌（ＨＰ）是胃炎和胃溃疡的重要病原体,越年越多的流行病学调查表明,ＨＰ的感染与胃癌的发生也密切相关,因而对其致癌机制的研究日益成为人们关注的热点。但目前对其机制所知不多,有关文章主要分析了ＨＰ感染所引起的炎性刺激,ＨＰ感染对人染色体结构和功能的改变,以及ＨＰ感染所致细胞程序性死亡变化对肿瘤发生的影响。本文就将这几方面的内容作一综述。     

Brazilian green propolis on Helicobacter pylori infection. a pilot clinical study

Recent in vitro studies suggest that propolis and some of its phenolic components are able to inhibit Helicobacter pylori growth. To date, there are no clinical studies. AIMS: To evaluate the effect of Brazilian green propolis on H. pylori-infected individuals. PATIENTS AND METHODS: Eighteen (11 females, 7 males, mean age 47 years) participants were included. Before treatment, all participants were submitted to gastroscopy, and H. pylori infection was confirmed by histology, urease test, and (13)C-urea breath test (UBT). Participants with UBT showing a delta over baseline (DOB) value higher than 4 per thousand were considered positive for H. pylori infection. Twenty drops from an alcoholic preparation of Brazilian green propolis were administered three times a day for 7 days. Clinical evaluation and UBT were performed at 1-3 days and at 40 days after the end of therapy to evaluate H. pylori suppression or eradication, respectively. RESULTS: All participants took all medication and completed the study. Eighty-three percent of the subjects did not succeed in suppressing or eradicating H. pylori. Two participants reached partial suppression after treatment, but became positive again at UBT performed 40 days after treatment. Another participant presented negative at UBT 40 days after treatment, not confirmed by a second UBT performed 100 days after treatment. CONCLUSIONS: Brazilian green propolis used in popular dose showed minimal effect on H. pylori infection. Larger studies with longer duration, larger dose, and different frequency of administration of propolis extract should be undertaken to define its role on H. pylori therapy.     

Helicobacter pylori associated with glossitis and halitosis

BACKGROUND: Helicobacter pylori is a curved microaerophilic Gram-negative bacterium considered as a risk factor for gastric cancer. The aim of this study was to find an association between burning sensations, acid taste, halitosis, and lingual hyperplasia with the effect of H. pylori on the mouth. MATERIALS AND METHODS: A total of 124 subjects with different gastric diseases were studied: 46 patients with burning, halitosis and lingual dorsum hyperplasia and 78 patients with other diseases. RESULTS: The detection of H. pylori in the oral cavity by histopathologic diagnosis and molecular biology was confirmed in 40/46 (87%) patients with burning, halitosis, and lingual hyperplasia, and in 2/78 (2.6%) subjects with other diseases. Chi2: 91.26 (p < .001) Mantel-Haenszel. CONCLUSION: This trial showed an association between H. pylori and burning, halitosis, and lingual hyperplasia, and further considered this bacterium a risk factor for gastric infection.     

Possible relationship between Helicobacter pylori infection and cap polyposis of the colon

BACKGROUND: Cap polyposis is a rarely encountered disease characterized by multiple distinctive inflammatory colonic polyps located from the rectum to the distal colon. The etiology of this disease is still unknown, and no specific treatment has been established. AIM: We report three cases of cap polyposis that were cured following eradication therapy for Helicobacter pylori infection. METHODS AND RESULTS: Three women were referred to Shinshu University Hospital because of mucoid and/or bloody diarrhea. Laboratory data showed hypoproteinemia in all cases; markers of inflammation such as C-reactive protein were negative. Colonoscopy revealed multiple sessile polyps with mucus adherent on the apices of the mucosal folds in the rectum and/or the sigmoid colon. The intervening mucosa was normal. Microscopic examinations of biopsy specimens taken from sessile polyps revealed inflamed mucosa with elongated tortuous crypts attenuated towards the mucosal surface. A granulation tissue 'cap' was observed on the surface of the mucosa. Various treatments were unsuccessful, including administration of metronidazole or prednisolone, avoidance of straining at defecation, and surgical or endoscopic resection. All were diagnosed with H. pylori infection in the stomach. Helicobacter pylori was not detected in the biopsy specimens from the colonic inflammatory polyps by immunohistochemical study using polyclonal anti-H. pylori antibody. After successful eradication therapy the clinical symptoms improved. Disappearance of cap polyposis was confirmed by colonoscopy in all three cases. CONCLUSION: We speculate that H. pylori infection might play a role in the pathogenesis of cap polyposis.     

幽门螺杆菌感染与脑梗死复发的关系及其机制研究

目的探讨幽门螺杆菌(HP)感染与脑梗死复发的相关性及其作用机制,为抗HP治疗降低脑梗死复发率提供依据。方法对我院神经内科收治的600例初发脑梗死患者,采用碳14呼气试验来定性HP感染患者,其中HP阴性患者197例为对照组(A组),HP阳性患者403例中,203例行标准三联疗法的患者为HP阳性治疗组(B组),200例未行抗HP治疗的患者为HP阳性观察组(C组)。所有患者均采用免疫投射比浊法定量血清超敏C反应蛋白(CRP),采用荧光偏振免疫测定法定量同型半胱氨酸(HCY),并进行为期3年的随访,比较3组患者的脑梗死复发率和CRP、HCY水平。结果 3组患者中,在随访期间复发率为HP阳性观察组为38.77%,HP阳性治疗组为25.37%,HP阴性对照组为20.51%。结论 HP感染与脑梗死有相关性,可通过作用于CRP和HCY加重动脉硬化,而增加脑梗死复发率。     

Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection

BACKGROUND: Different kinds of proton pump inhibitor-based triple therapies could result in different Helicobacter pylori eradication rates. AIM: The aims of this study were to compare the efficacy and safety of rabeprazole- and esomeprazole-based triple therapy in primary treatment of H. pylori infection in Taiwan. PATIENTS AND METHODS: From June 2005 to March 2007, 420 H. pylori-infected patients were randomly assigned to receive a 7-day eradication therapy with either esomeprazole 40 mg daily (EAC group, n = 209) or rabeprazole 20 mg b.i.d. (RAC group, n = 211) in combination with amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d.. Follow-up endoscopy with biopsy was done 12-16 weeks after completion of eradication therapy. Those who refused endoscopic exams underwent (13)C-urea breath test to assess the treatment response. RESULTS: Intention-to-treat analysis revealed that the eradication rate was 89.4% in the EAC group and 90.5% in RAC groups (p-value = .72). All of the subjects returned for assessment of compliance (100% in EAC group vs. 99.5% in RAC group, p-value = .32) and adverse events (3.83% in EAC group vs. 6.16% in RAC group, p-value = .27). Sixty (28.7%) and 37 (17.6%) patients in EAC and RAC group, respectively, refused endoscopy and underwent a (13)C-urea breath test to determine the treatment effect. CONCLUSION: In conclusion, rabeprazole- and esomeprazole-based primary therapies for H. pylori infection are comparable in efficacy and safety.     

326例儿童缺铁性贫血与感染幽门螺杆菌关系探究

目的分析幽门螺杆菌(H.pylori)对儿童缺铁性贫血(IDA)的影响,探讨H.pylori感染与儿童IDA的相关性,提高儿童IDA诊治率。方法应用~(13)C-呼气试验和胶体金法检测326例IDA患儿及211例健康儿童H.pylori感染情况,并对其结果进行统计学分析。结果 326例IDA患儿中H.pylori检测阳性217例(阳性率为66.56%),健康组儿童H.pylori检测阳性47例(阳性率为22.27%),两组比较差异有统计学意义(X~2=100.54,P0.01)。2-6岁组分别与7-9岁组及10-12岁组H.pylori阳性率比较差异均有统计学意义(X~2=8.61、21.46,P0.05),7-9岁组较10-12组H.pylori阳性率比较差异无统计学意义(X~2=2.62,P0.05)。其中女患儿H.pylori阳性率为78.06%(121/155),男患儿H.pylori阳性率为56.14%(96/171),两者比较差异有统计学意义(X~2=17.55,P0.01),且不同年龄组男女阳性率比较差异均有统计学意义。217例H.pylori感染的IDA患儿以轻度贫血为主,占95.85%(208/217)。结论H.pylori感染与儿童IDA之间存在相关性。